Skip to content

DECIDE-HF: Heart Rate Variability in Heart Failure Patients

DECIDE-HF - Heart Rate Variability in Heart Failure Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00949676
Acronym
DECIDE-HF
Enrollment
60
Registered
2009-07-30
Start date
2009-09-30
Completion date
2013-12-31
Last updated
2013-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systolic Heart Failure

Brief summary

The purpose of this study is to determine whether heart rate variability-like parameters are related to changes in the disease status of a subject that suffers from a disease that decreases the pumping function of the heart.

Interventions

None listed

Sponsors

Medtronic BRC
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject has signed and dated the study-specific informed consent form * Subject is 18 years of age or older * Subject is expected to remain available for follow-ups * Subject is able and willing to comply with the protocol requirements * Subject has predominant Normal Sinus Rhythm * Subject has systolic Heart Failure and is at the moment of enrollment in NYHA class II or III and has an ejection fraction of less then 40% * Subject has had a HF-related hospitalization in the past 12 months

Exclusion criteria

* Subject needs permanent atrial pacing (\> 10%) * Subject has intermittent 2nd or intermittent 3rd degree block * Subject has persistent or permanent AF * Subject has Long QT syndrome, Brugada syndrome, Jervell and Lange- Nielsen syndrome, Romano-Ward syndrome, Andersen-Tawil syndrome or Timothy's syndrome * Subject has had recent (\<2 months) acute coronary syndrome * Subject has had recent (\<2 months) revascularization * Subject has a pending cardiac transplant or revascularization * Subject has severe stenotic valvular heart disease * Subject has severe pulmonary (forced expiratory volume in 1 s \< 1 L) hepatic or renal (plasma creatinine \> 0.2 mmol/L) disease * Subject is participating in another study that may affect the results of this study

Design outcomes

Primary

MeasureTime frame
HF diagnostic2 years

Countries

Belgium, Germany, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026